Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 5Terminated 2

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Melanoma 4Uveal Melanoma 2

Interventions

pembrolizumab 3Nivolumab 3Ipilimumab 3Cyclophosphamide 3Radiosurgery 2MART-1 Antigen 2CTLA-4 Antigen 2ulixertinib 1sotrastaurin 1siremadlin 1relatlimab 1pentetreotide 1oblimersen 1incomplete Freund's adjuvant 1fotemustine 1fludarabine phosphate 1fludarabine 1entrectinib 1defactinib 1binimetinib 1benzamide 1aldesleukin 1aflibercept 1Valacyclovir 1Toll-Like Receptor 1 1TYRP1 protein, human 1Sunitinib 1Standard of Care 1RO5126766 1RNA, Messenger 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Uveal Melanoma × MART-1 Antigen × Clear all
NCT00005841 2014-05-22

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

University of Southern California

Phase 1 Terminated
15 enrolled
Dermatologic

Uveal Melanoma, Melanoma

NCT00036816 2012-09-24

Vaccine Therapy in Treating Patients With Melanoma of the Eye

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3 Terminated
13 enrolled
Dermatologic

Uveal Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡